IN2014DN03325A - - Google Patents
Info
- Publication number
- IN2014DN03325A IN2014DN03325A IN3325DEN2014A IN2014DN03325A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A IN 3325DEN2014 A IN3325DEN2014 A IN 3325DEN2014A IN 2014DN03325 A IN2014DN03325 A IN 2014DN03325A
- Authority
- IN
- India
- Prior art keywords
- compound
- directed
- composition
- sulphur
- selene
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 239000005864 Sulphur Substances 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical group NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 abstract 1
- 241000791876 Selene Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 125000000962 organic group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161543510P | 2011-10-05 | 2011-10-05 | |
| NL2007536A NL2007536C2 (en) | 2011-10-05 | 2011-10-05 | Adjuvant compound. |
| US201261615566P | 2012-03-26 | 2012-03-26 | |
| PCT/NL2012/050694 WO2013051936A1 (en) | 2011-10-05 | 2012-10-04 | Adjuvant compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN03325A true IN2014DN03325A (en:Method) | 2015-06-26 |
Family
ID=48043964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3325DEN2014 IN2014DN03325A (en:Method) | 2011-10-05 | 2012-10-04 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9314521B2 (en:Method) |
| EP (1) | EP2763697B9 (en:Method) |
| JP (1) | JP6099210B2 (en:Method) |
| KR (1) | KR102053699B1 (en:Method) |
| CN (1) | CN104244976B (en:Method) |
| AU (1) | AU2012319265B2 (en:Method) |
| BR (1) | BR112014008214B1 (en:Method) |
| CA (1) | CA2886631C (en:Method) |
| EA (1) | EA030741B1 (en:Method) |
| ES (1) | ES2952644T3 (en:Method) |
| IL (1) | IL231951B (en:Method) |
| IN (1) | IN2014DN03325A (en:Method) |
| MX (1) | MX356028B (en:Method) |
| NL (1) | NL2007536C2 (en:Method) |
| SG (1) | SG11201401291XA (en:Method) |
| WO (1) | WO2013051936A1 (en:Method) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2976325B1 (en) | 2013-03-21 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Synthesis of cyclic imide containing peptide products |
| WO2014147124A1 (en) | 2013-03-21 | 2014-09-25 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| EP3604271A1 (en) | 2013-06-28 | 2020-02-05 | Auckland Uniservices Limited | Peptides for amino acid and peptide conjugates and conjugation process |
| ES2979072T3 (es) | 2014-06-02 | 2024-09-24 | Isa Pharmaceuticals B V | Péptidos largos sintéticos (SLP) para la vacunación terapéutica contra la infección por el virus de la hepatitis B |
| JP2018505152A (ja) | 2014-12-23 | 2018-02-22 | アン ブリンブル マーガレット | アミノ酸複合体及びペプチド複合体ならびにそれらの使用 |
| GB201521894D0 (en) * | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| PE20230343A1 (es) | 2015-12-11 | 2023-03-01 | Immatics Biotechnologies Gmbh | Peptidos que estimulan respuestas inmunitarias antitumorales |
| EP3419962A4 (en) | 2016-02-26 | 2020-03-11 | Auckland Uniservices Limited | CONJUGATES OF AMINO ACIDS AND PEPTIDES AND CONJUGATION METHOD |
| CA3027459A1 (en) | 2016-06-20 | 2017-12-28 | Isa Pharmaceuticals B.V. | Formulation of a peptide vaccine |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| CA3057715A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| WO2019122050A1 (en) | 2017-12-22 | 2019-06-27 | Isa Pharmaceuticals B.V. | Methods of immunization |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| WO2021110919A1 (en) | 2019-12-07 | 2021-06-10 | Isa Pharmaceuticals | Treatment of diseases related to hepatitis b virus |
| US20230087422A1 (en) | 2020-02-07 | 2023-03-23 | Isa Pharmaceuticals B.V. | Treatment of hpv-related diseases |
| US20230143215A1 (en) | 2020-04-23 | 2023-05-11 | Isa Pharmaceuticals B.V. | Immunization against sars-cov-related diseases |
| KR20240029765A (ko) | 2021-07-12 | 2024-03-06 | 아이에스에이 파마슈티컬즈 비.브이. | 복잡한 혼합물에서의 개선된 물질 정량화 |
| WO2024068636A1 (en) | 2022-09-27 | 2024-04-04 | Isa Pharmaceuticals B.V. | Adjuvanted immunogenic peptides for intradermal administration |
| EP4601685A1 (en) | 2022-10-13 | 2025-08-20 | Isabella Pharma B.V. | Modified long peptides suitable for use in immunisation |
| WO2024149888A1 (en) | 2023-01-12 | 2024-07-18 | Isa Pharmaceuticals B.V. | Improved lipopeptide quantification |
| WO2025008085A1 (en) | 2023-07-05 | 2025-01-09 | Isa Pharmaceuticals B.V. | Immunotherapy for the treatment of prame-expressing cancers |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0114787B1 (de) * | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| DE3937412A1 (de) * | 1989-11-10 | 1991-05-16 | Hoechst Ag | Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten |
| US6024964A (en) * | 1985-06-24 | 2000-02-15 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| US20030211510A1 (en) | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6686447B1 (en) | 1999-06-30 | 2004-02-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6504010B1 (en) | 1999-06-30 | 2003-01-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| AR032743A1 (es) | 1999-06-30 | 2003-11-26 | Corixa Corp | Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon |
| NL1012739C2 (nl) | 1999-07-29 | 2001-01-30 | Maasland Nv | Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer. |
| US7202034B2 (en) | 2000-12-08 | 2007-04-10 | Academisch Ziekenhuis Leiden | Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
| MXNL04000056A (es) | 2004-06-30 | 2006-01-11 | Mario Alberto Aguilera Rico | Sistema de construccion terra acero. |
| EP2061507A4 (en) * | 2006-08-14 | 2010-08-18 | Thymon Llc | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF SEVERAL HIV-1 STRAINS AND SUB-TYPES |
| CN106220721B (zh) | 2007-03-26 | 2020-04-07 | 莱顿大学医学中心附属莱顿教学医院 | Prame衍生的肽以及包括该肽的免疫原组合物 |
| AU2008257791B2 (en) | 2007-05-31 | 2013-03-28 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | P53 peptide vaccine |
| ES2411059T3 (es) | 2007-05-31 | 2013-07-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Epítopos de HPV objetivos de células T que infiltran malignidades cervicales para su uso en vacunas |
| KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 |
| JP5848748B2 (ja) * | 2010-03-23 | 2016-01-27 | アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ | 感染症、炎症、呼吸器疾患などの処置に使用するｔｌｒ２アゴニストとしての化合物（システインベースのリポペプチド）および組成物 |
-
2011
- 2011-10-05 NL NL2007536A patent/NL2007536C2/en active
-
2012
- 2012-10-04 EA EA201490709A patent/EA030741B1/ru not_active IP Right Cessation
- 2012-10-04 KR KR1020147012025A patent/KR102053699B1/ko active Active
- 2012-10-04 CA CA2886631A patent/CA2886631C/en active Active
- 2012-10-04 ES ES12780309T patent/ES2952644T3/es active Active
- 2012-10-04 WO PCT/NL2012/050694 patent/WO2013051936A1/en not_active Ceased
- 2012-10-04 JP JP2014534504A patent/JP6099210B2/ja active Active
- 2012-10-04 BR BR112014008214-6A patent/BR112014008214B1/pt active IP Right Grant
- 2012-10-04 AU AU2012319265A patent/AU2012319265B2/en active Active
- 2012-10-04 SG SG11201401291XA patent/SG11201401291XA/en unknown
- 2012-10-04 US US14/349,652 patent/US9314521B2/en active Active
- 2012-10-04 IN IN3325DEN2014 patent/IN2014DN03325A/en unknown
- 2012-10-04 EP EP12780309.6A patent/EP2763697B9/en active Active
- 2012-10-04 MX MX2014004114A patent/MX356028B/es active IP Right Grant
- 2012-10-04 CN CN201280059738.4A patent/CN104244976B/zh active Active
-
2014
- 2014-04-03 IL IL231951A patent/IL231951B/en active IP Right Grant
-
2016
- 2016-03-07 US US15/062,589 patent/US9770506B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140093673A (ko) | 2014-07-28 |
| CN104244976B (zh) | 2017-05-31 |
| NL2007536C2 (en) | 2013-04-08 |
| US9314521B2 (en) | 2016-04-19 |
| MX356028B (es) | 2018-05-09 |
| EP2763697B9 (en) | 2023-10-04 |
| CA2886631A1 (en) | 2013-04-11 |
| US20160250325A1 (en) | 2016-09-01 |
| AU2012319265A1 (en) | 2014-05-22 |
| US9770506B2 (en) | 2017-09-26 |
| JP6099210B2 (ja) | 2017-03-22 |
| CN104244976A (zh) | 2014-12-24 |
| EA201490709A1 (ru) | 2014-09-30 |
| NZ623869A (en) | 2015-11-27 |
| IL231951B (en) | 2019-08-29 |
| IL231951A0 (en) | 2014-05-28 |
| ES2952644T3 (es) | 2023-11-02 |
| AU2012319265B2 (en) | 2016-10-13 |
| EA030741B1 (ru) | 2018-09-28 |
| EP2763697C0 (en) | 2023-06-07 |
| EP2763697B8 (en) | 2023-07-12 |
| KR102053699B1 (ko) | 2019-12-09 |
| EP2763697A1 (en) | 2014-08-13 |
| US20150104473A1 (en) | 2015-04-16 |
| CA2886631C (en) | 2019-06-11 |
| EP2763697B1 (en) | 2023-06-07 |
| MX2014004114A (es) | 2014-10-17 |
| BR112014008214A2 (pt) | 2017-06-13 |
| SG11201401291XA (en) | 2014-05-29 |
| WO2013051936A1 (en) | 2013-04-11 |
| WO2013051936A9 (en) | 2013-09-12 |
| JP2014530808A (ja) | 2014-11-20 |
| BR112014008214B1 (pt) | 2022-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN03325A (en:Method) | ||
| WO2016077464A8 (en) | Amino acid derivatives and their uses | |
| BR112012007411A2 (pt) | composto, processo para sua preparação e composição farmacêutica contendo o mesmo | |
| MY200083A (en) | Cyclic dinucleotide compounds | |
| TR201900128T4 (tr) | Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller. | |
| MX2010007587A (es) | Compuestos que comprenden un grupo ciclobutoxi. | |
| PH12012501918A1 (en) | Process for preparation of dopo-derived compounds and compositions thereof | |
| MX2012002502A (es) | Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos. | |
| MY150596A (en) | Hsp90 inhibitors | |
| BR112013020996A2 (pt) | derivados aminobutíricos substituídos como inibidores de neprilisina | |
| PH12012502352A1 (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
| JO2910B1 (en) | Organic compounds | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| MX2011007952A (es) | Tricianoboratos novedosos. | |
| MX2013000295A (es) | Procedimiento de preparacion de un inhibidor especifico de la trombina. | |
| MX352607B (es) | Proceso para la preparacion de benzoxaboroles. | |
| PH12013500694A1 (en) | Process for manufacturing dihydropteridinones and intermediates thereof | |
| WO2009137444A3 (en) | Cure accelerators for anaerobic curable compositions | |
| MY167638A (en) | Treatment composition for textile goods | |
| NZ704155A (en) | Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof | |
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| MX2013003387A (es) | Proceso para preparacion de producto de reaccion de urea ciclica y de aldehido multifuncional. | |
| UY32975A (es) | Derivados de aminopiridina | |
| BR112013024361A2 (pt) | novos compostos de azaspirodecanona como inibidores de hsl | |
| EA201390170A1 (ru) | Составы |